162 related articles for article (PubMed ID: 10669812)
21. Drug development for orphan diseases in the context of personalized medicine.
Brewer GJ
Transl Res; 2009 Dec; 154(6):314-22. PubMed ID: 19931198
[TBL] [Abstract][Full Text] [Related]
22. [Status of research and development for control of tropical diseases: hypocrisy, indifference or lack of coordination].
Millet P
Med Trop (Mars); 2006 Dec; 66(6):542-8. PubMed ID: 17286017
[TBL] [Abstract][Full Text] [Related]
23. [European ordinance on orphan drugs: changes and threats].
Linthorst GE; Hollak CE
Ned Tijdschr Geneeskd; 2003 Jan; 147(4):143-5. PubMed ID: 12635543
[TBL] [Abstract][Full Text] [Related]
24. Paying a high price for low costs: why there should be no legal constraints on the profits that can be made on drugs for tropical diseases.
Sonderholm J
J Med Ethics; 2009 May; 35(5):315-9. PubMed ID: 19407038
[TBL] [Abstract][Full Text] [Related]
25. Challenges and opportunities in developing and marketing vaccines for OIE List A and emerging animal diseases.
Gay CG; Salt J; Balaski C
Dev Biol (Basel); 2003; 114():243-50. PubMed ID: 14677694
[TBL] [Abstract][Full Text] [Related]
26. Initial lessons from public-private partnerships in drug and vaccine development.
Wheeler C; Berkley S
Bull World Health Organ; 2001; 79(8):728-34. PubMed ID: 11545329
[TBL] [Abstract][Full Text] [Related]
27. Mission possible.
Hopkins AL; Witty MJ; Nwaka S
Nature; 2007 Sep; 449(7159):166-9. PubMed ID: 17851512
[No Abstract] [Full Text] [Related]
28. [Tropical climate pathology].
Besancenot JP
Med Trop (Mars); 1997; 57(4 Bis):431-5. PubMed ID: 9612744
[TBL] [Abstract][Full Text] [Related]
29. Can we help one billion sick people?
Maliski E; Gund P; Brown F
Curr Opin Drug Discov Devel; 2008 May; 11(3):301-2. PubMed ID: 18428082
[No Abstract] [Full Text] [Related]
30. Biosensors as rapid diagnostic tests for tropical diseases.
Rodrigues Ribeiro Teles FS; Pires de Távora Tavira LA; Pina da Fonseca LJ
Crit Rev Clin Lab Sci; 2010; 47(3):139-69. PubMed ID: 21155631
[TBL] [Abstract][Full Text] [Related]
31. Criteria supporting the study of drugs in the newborn.
Ward RM; Benitz WE; Benjamin DK; Blackmon L; Giacoia GP; Hudak M; Lasky T; Rodriguez W; Selen A
Clin Ther; 2006 Sep; 28(9):1385-98. PubMed ID: 17062311
[TBL] [Abstract][Full Text] [Related]
32. [Contraceptive development--the view from the U.S.A. in the mid 80s].
Potts M; Siemens A; Burton N
Contracept Fertil Sex (Paris); 1986 Mar; 14(3):247-51. PubMed ID: 12268061
[TBL] [Abstract][Full Text] [Related]
33. [Orphan drugs and orphan diseases].
Campos-Castelló J
Rev Neurol; 2001 Aug 1-15; 33(3):216-20. PubMed ID: 11588712
[TBL] [Abstract][Full Text] [Related]
34. Understanding orphan drug regulations: an EU and U.S. comparative analysis.
Grienenberger A
J Biolaw Bus; 2004; 7(3):58-61. PubMed ID: 15460604
[TBL] [Abstract][Full Text] [Related]
35. [Scientific standards in parasitology in historical perspective].
Lonc E; Płonka-Syroka B
Wiad Parazytol; 2005; 51(3):197-207. PubMed ID: 16913523
[TBL] [Abstract][Full Text] [Related]
36. [Orphan drugs--medications for patients with rare diseases].
Thielke D; Thyssen JP; Hansen BJ
Ugeskr Laeger; 2006 Jun; 168(23):2236-8. PubMed ID: 16768975
[TBL] [Abstract][Full Text] [Related]
37. Perspectives on stimulating industrial research and development for neglected infectious diseases.
Webber D; Kremer M
Bull World Health Organ; 2001; 79(8):735-41. PubMed ID: 11545330
[TBL] [Abstract][Full Text] [Related]
38. FDA launches priority vouchers for neglected-disease drugs.
Waltz E
Nat Biotechnol; 2008 Dec; 26(12):1315-6. PubMed ID: 19060849
[No Abstract] [Full Text] [Related]
39. Quantifying emerging drugs for very rare conditions.
Miles KA; Packer C; Stevens A
QJM; 2007 May; 100(5):291-5. PubMed ID: 17456610
[TBL] [Abstract][Full Text] [Related]
40. Spread of infectious diseases continues. International (North and South America).
AIDS Wkly Plus; 1996 Jun; ():14-6. PubMed ID: 12291118
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
